The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a ribbon‑tying event to mark the launch of a unified nonprofit research organization in New York City. JAX leaders, including president Lon Cardon, and guests such as Francis Collins, framed the union as a research engine combining JAX’s mouse genetics strengths with NYSCF’s stem‑cell automation. Executives cited translational ambitions, including rapid custom gene therapy development highlighted by the Baby KJ case, and signaled investments in scalable platforms for genomic and stem‑cell research.